查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1947975

全球暴露前预防市场（按产品类型、剂型、分销管道和最终用户划分）预测（2026-2032年）

Pre-Exposure Prophylaxis Market by Product Type, Form, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，暴露前预防 (PrEP) 市场价值将达到 19.2 亿美元，到 2026 年将成长至 20.4 亿美元，复合年增长率为 7.44%，到 2032 年将达到 31.8 亿美元。

关键市场统计数据
基准年 2025 19.2亿美元
预计年份：2026年 20.4亿美元
预测年份 2032 31.8亿美元
复合年增长率 (%) 7.44%

暴露前预防（PrEP）策略实施：一个涵盖临床进展、卫生系统整合和预防优先事项的框架，塑造当代公共卫生应对措施

暴露前预防（PrEP）处于生物医学创新、公共卫生政策和社区主导的预防工作的关键交汇点。过去十年，PrEP已从一项小众临床干预措施发展成为公认的爱滋病预防支柱，这得益于大量证据证明，当与持续坚持治疗方案和支持性服务相结合时，PrEP具有显着的有效性。如今，临床医生、公共卫生官员和倡议团体不仅关注药物疗效，也关注能够确保持续获得​​PrEP的系统，包括定期筛检、依从性支持和消除歧视的就医途径。

分析重塑PrEP服务提供方式的关键结构性变化，包括治疗方法创新、数位化照护模式以及推动策略重组的竞争压力

PrEP领域经历了许多变革，这些变革正同时改变临床实务和市场行为。药物多样化，特别是长效注射剂与口服製剂的临床应用，扩大了患者和临床医生的选择范围，并促使人们重新审视用药依从治疗方法模式和给药基础设施。同时，学名药的扩张也带来了新的竞争动态，影响着筹资策略、价格谈判和付款方的议价能力。

重点评估美国关税变化对供应链、分销系统和支付方决策中预防性治疗取得途径​​的影响。

影响药品进口和供应链的政策和贸易措施直接影响暴露前预防（PrEP）生态系统中的供应、价格波动和製造商决策。关税调整和进口限制会增加活性药物成分、辅料和成品物流的营运成本，可能迫使製造商和经销商重新评估其筹资策略和生产地点。为此，一些製造商可能会加快生产本地化进程或使其供应商网路多元化，以确保供应连续性免受关税波动的影响。

可操作的細項分析揭示了产品类型、剂量形式、通路选择和最终用户环境如何相互作用，从而影响实际的 PrEP 交付和获取。

细分市场层面的趋势揭示了临床偏好、采购选择和分销实践相互交织，共同影响药物可及性和应用的领域。就产品类型而言，相关人员必须权衡品牌药的现有地位（例如作为临床标准的领先口服疗法）与学名药日益增长的市场份额（后者正在改变成本结构和购买行为）。在品牌药产品组合中，即使新的治疗方案不断出现，但某些现有产品仍在影响处方模式。同样重要的是剂型方面的差异：注射剂需要在诊所内给药，需要低温运输管理以及不同的用药支持模式，而口服药物则更注重药房供应和患者自我管理。

从区域比较观点，探讨法规结构、健康系统能力和社区参与如何驱动全球不同的暴露前预防（PrEP）采用模式。

法规环境、医疗基础设施和社会因素的区域差异导致全球市场中暴露前预防（PrEP）的采纳和使用模式各不相同。在美洲，公共卫生计画和社区组织在扩大预防服务的覆盖范围和提高其使用率方面发挥了核心作用，但服务集中在都市区与需要将服务覆盖范围扩展到农村和医疗服务不足地区之间存在着明显的矛盾。欧洲、中东和非洲（EMEA）地区的许多国家有着截然不同的监管路径和资金筹措机制。这种多样性影响着产品的可及性、学名药在公共采购中的作用，以及医疗系统支持以诊所或社区为基础的服务模式的能力。

简要概述产业竞争动态，重点介绍製造商、经销商和服务提供者影响竞争的策略措施。

製造商、经销商和服务提供者之间的竞争动态正在塑造预防产品组合和商业策略的未来发展方向。现有製药公司持续投资于核心产品的生命週期管理，并推动下一代製剂的研发，以巩固其治疗优势。新参与企业和非专利生产商加剧了价格竞争，并扩大了处方笺选择范围，这促使现有企业透过疗效数据、患者援助计划以及与支付方和诊所的合作来寻求差异化竞争。

为产业领导者提供策略性和可操作性的建议，以保障预防性疗法的可近性、优化交付模式并促进其公平普及。

对于希望提升专案成效的领导者，我们建议采取一系列协调一致的倡议，同时改善供应、获取途径和病患体验。首先，应实现采购和生产策略多元化，减少对单一国家的依赖以及关税带来的成本压力，并在条件允许的情况下投资国内或区域生产。其次，应根据不同的医疗环境调整产品系列，使产品组合与供给能力相符。例如，应优先发展诊所计画并加强长效注射剂的培训，同时确保优化口服疗法的药房管道。

我们采用透明、稳健的混合方法调查方法，结合相关人员访谈、政策分析和供应链情境映射，得出策略意义。

我们的研究方法融合了定性和定量技术，旨在建立全面的证据基础，同时也认识到其固有的局限性。主要研究包括对临床研究人员、感染疾病专家、采购负责人、支付者和患者权益倡导团体进行深入访谈，以了解他们对临床应用、供应链限制和患者偏好的实地观点。次要研究资料包括监管指南、临床试验论文和政策文件，用于检验临床特征和核准时间表。我们对这些资讯进行了三角验证，以确保其一致性并突出不同相关人员之间的差异。

简明扼要的结论整合了临床进展、系统准备和政策槓桿，这些因素决定了预防策略的公平影响。

全面的证据表明，预防性医疗保健领域正经历快速演变，产品创新、服务模式和政策选择共同决定医疗服务的可近性和公平性。长效製剂和多元化的产品系列拓展了临床选择，但其影响取决于医疗系统的准备情况、支付方的合作以及针对最需要帮助人群的精准推广。受学名药和贸易政策影响的成本趋势将影响采购决策和公共专案的永续性，进一步凸显了积极主动的供应链管理和策略性支付方参与的必要性。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按产品类型分類的暴露前预防市场

  • 品牌产品
    • 德斯科比
    • Truvada
  • 学名药

9. 按剂型分類的暴露前预防市场

  • 注射
  • 口服

第十章 按分销管道分類的暴露前预防市场

  • 网路药房
  • 线下药房

第十一章 按最终用户分類的暴露前预防市场

  • 诊所
  • 居家照护
  • 医院

第十二章 各地区的暴露前预防市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 按组别分類的暴露前预防市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国暴露前预防市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国暴露前预防市场

第十六章：中国的暴露前预防药物市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Accord Healthcare Inc.
  • Amneal Pharmaceuticals, Inc.
  • Aurobindo Pharma Ltd.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius Kabi AG
  • Gilead Sciences, Inc.
  • Hetero Labs Limited
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan NV
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • ViiV Healthcare Limited
Product Code: MRR-4F7A6D4FB6B9

The Pre-Exposure Prophylaxis Market was valued at USD 1.92 billion in 2025 and is projected to grow to USD 2.04 billion in 2026, with a CAGR of 7.44%, reaching USD 3.18 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.92 billion
Estimated Year [2026] USD 2.04 billion
Forecast Year [2032] USD 3.18 billion
CAGR (%) 7.44%

A strategic introduction to Pre-Exposure Prophylaxis that frames clinical advances, health system integration, and prevention priorities shaping modern public health responses

Pre-exposure prophylaxis (PrEP) sits at a pivotal intersection of biomedical innovation, public health policy, and community-led prevention. Over the last decade, PrEP shifted from a niche clinical intervention to a widely recognized pillar of HIV prevention, driven by robust evidence demonstrating efficacy when regimens are taken consistently and paired with supportive services. Clinicians, public health authorities, and advocacy groups now emphasize not only pharmacologic effectiveness but also the systems that enable sustained access, including routine screening, adherence support, and destigmatized care pathways.

Consequently, programmatic attention has expanded beyond clinical trials to real-world implementation: integration into primary care, targeted outreach to populations at highest risk, and the development of differentiated service delivery models. Advances in biomedical options, such as long-acting injectables alongside established oral regimens, are reshaping clinical algorithms and patient preferences. At the same time, regulatory decisions, payer policies, and supply chain dynamics influence the pace and equity of uptake. For stakeholders, the imperative is clear: design prevention strategies that marry clinical efficacy with scalable, sustainable delivery models that reach marginalized and geographically dispersed populations.

An analysis of the major structural shifts reshaping PrEP delivery including therapeutic innovation, digital care models, and competitive pressures driving strategic realignment

The landscape of PrEP has undergone several transformative shifts that are altering clinical practice and market behavior in tandem. Pharmacologic diversification, most notably the clinical adoption of long-acting injectable agents alongside oral products, has broadened the range of options for patients and clinicians, prompting reexamination of adherence paradigms and delivery infrastructure. Parallel to therapeutic innovation, the expansion of generic formulations has introduced new competitive dynamics that influence procurement strategies, pricing negotiations, and the bargaining power of payers.

Simultaneously, digital health tools and telemedicine have matured into practical enablers of PrEP initiation and follow-up care, allowing remote screening, virtual counseling, and adherence monitoring to link with pharmacy delivery models. Health systems and community-based organizations are increasingly leveraging data-driven outreach and combination prevention approaches to identify and engage underserved groups. As regulatory frameworks evolve to accommodate novel formulations and prescribing models, stakeholders must adapt contracting, training, and distribution systems. Taken together, these shifts necessitate integrated planning across clinical, commercial, and policy domains to translate scientific progress into equitable public health gains.

A focused evaluation of how tariff changes in the United States can cascade through supply chains, distribution systems, and payer decisions to affect access to prevention therapies

Policy and trade actions affecting pharmaceutical imports and supply chains exert a proximal influence on availability, pricing dynamics, and manufacturer decision-making in the PrEP ecosystem. Tariff adjustments and import restrictions can increase the operational cost of active pharmaceutical ingredients, excipients, and finished product logistics, which in turn can prompt manufacturers and distributors to reevaluate sourcing strategies and production footprints. In response, several manufacturers may accelerate localization of manufacturing or diversify supplier networks to insulate supply continuity from tariff volatility.

Beyond manufacturing, tariff-related cost pressures can ripple through distribution channels, influencing inventory strategies at hospital and retail pharmacies as well as online fulfillment arrangements. Payers and health systems may respond by prioritizing procurement of lower-cost generic alternatives or by renegotiating contracts to preserve patient access. Meanwhile, regulatory agencies and advocacy groups often intensify efforts to mitigate access disruptions through streamlined approvals for alternative sources and collaborative procurement mechanisms. Ultimately, tariff policy is one of multiple levers that can reshape the economics of prevention programs; prudent stakeholders will assess tariff exposure, pursue supply diversification, and engage policymakers to protect affordability and continuity of care.

An actionable segmentation analysis revealing how product type, formulation, channel choices, and end-user settings converge to shape practical PrEP delivery and access

Segment-level dynamics illuminate where clinical preferences, procurement choices, and distribution practices intersect to influence access and uptake. In the context of product type, stakeholders must balance the established role of branded options-such as leading oral regimens that have served as clinical standards-with the growing presence of generic alternatives that alter cost structures and purchasing behavior; within branded portfolios, specific legacy products continue to shape prescribing patterns even as newer options enter practice. Form-related distinctions are equally consequential: injectable formulations demand clinic-based administration, cold-chain management, and different adherence support models compared with oral regimens, which emphasize pharmacy access and patient-managed dosing.

Distribution channel segmentation highlights operational and strategic trade-offs. Hospital pharmacies offer integrated clinical oversight and linkage to specialty care, while retail pharmacies provide convenient access for episodic refills and broad geographic reach; online pharmacies expand reach further but require robust verification and fulfillment capabilities. End-user settings create divergent service delivery models: clinics can deliver comprehensive counseling and laboratory monitoring, home care models can support adherence through remote monitoring and delivery services, and hospitals often manage initiation for more medically complex patients. Synthesizing these segment insights, effective strategies prioritize product-form fit to delivery capacity, align procurement with payer preferences, and design patient-centered pathways that leverage the strengths of each channel and end-user environment.

A comparative regional perspective that maps how regulatory frameworks, health system capacity, and community engagement drive divergent PrEP adoption patterns globally

Regional variability in regulatory environments, health infrastructure, and social determinants drives distinct patterns of PrEP deployment and uptake across global markets. In the Americas, national public health programs and community organizations have been central to expanding access and normalizing prevention services, with urban concentration of services contrasted by the need to extend reach to rural and underserved communities. In many countries within Europe, Middle East & Africa, regulatory pathways and financing mechanisms vary widely; this heterogeneity affects the timing of product availability, the role of generics in public procurement, and the capacity of health systems to support clinic-based or community-delivered models.

Across the Asia-Pacific region, a mixture of advanced healthcare systems and resource-constrained environments creates a patchwork of adoption scenarios. Some economies rapidly incorporate novel long-acting agents into practice where regulatory approvals and payer coverage align, while other markets rely heavily on generic oral options and targeted pilot programs. Cross-region collaborations, knowledge exchange, and pooled procurement initiatives increasingly offer mechanisms to address disparities, but success depends on tailoring strategies to local delivery realities, cultural contexts, and the robustness of laboratory and monitoring infrastructure.

A concise synthesis of industry competitive dynamics highlighting strategic maneuvers by manufacturers, distributors, and service providers that affect access and positioning

Competitive dynamics among manufacturers, distributors, and service providers are shaping the future direction of prevention portfolios and commercial strategies. Established pharmaceutical companies continue to invest in lifecycle management for core products while advancing next-generation formulations to defend therapeutic franchises. New market entrants and generic manufacturers intensify price competition and expand formulary options, prompting incumbent firms to differentiate through outcomes data, patient support programs, and partnerships with payers and clinics.

Strategic collaborations between pharmaceutical companies and contract manufacturers have become more prevalent as firms seek to scale production, manage cost exposure, and ensure supply chain redundancy. Additionally, alliances with digital health companies and specialty pharmacies enable integrated care pathways that improve adherence and retention. For decision-makers, the key implication is that competitive positioning increasingly depends on combined clinical evidence, service delivery capability, and the ability to demonstrate value to payers and providers in routine practice.

Strategic and implementable recommendations for industry leaders designed to protect access, optimize delivery models, and accelerate equitable uptake of prevention therapies

Leaders seeking to strengthen program impact should pursue a set of coordinated actions that address supply, access, and patient experience simultaneously. First, diversify sourcing and manufacturing strategies to reduce exposure to single-country supply disruptions and tariff-induced cost pressures, while investing in onshore or regional production where feasible. Second, align product portfolios with delivery capabilities by matching formulation choices to care settings; for example, prioritize clinic-based programs and training for long-acting injectables while ensuring pharmacy channels are optimized for oral regimens.

Third, engage payers and policymakers proactively to secure coverage pathways and enable innovative contracting arrangements that support equity-driven access. Fourth, invest in digital adherence tools, telehealth-enabled initiation pathways, and community-led outreach to lower barriers for underserved populations. Finally, measure outcomes through rigorous real-world evidence collection and use those insights to refine clinical guidelines, reimbursement negotiations, and programmatic priorities. By coordinating these actions, organizations can translate product-level advances into durable public health outcomes.

A transparent and robust mixed-methods research methodology that combines stakeholder interviews, policy analysis, and supply chain scenario mapping to derive strategic implications

The research approach integrates qualitative and quantitative techniques to construct a comprehensive evidence base while acknowledging inherent limitations. Primary research consisted of in-depth interviews with clinical investigators, infectious disease specialists, procurement officers, payers, and patient advocates to capture frontline perspectives on clinical adoption, supply chain constraints, and patient preferences. Secondary sources included regulatory guidance, clinical trial publications, and policy documents to verify clinical characteristics and approval timelines. Triangulation across these inputs ensured consistency and helped surface divergent stakeholder views.

Supply chain mapping and scenario analysis were used to evaluate exposure to trade policy shifts and to identify possible mitigation strategies. The methodology prioritized transparency in assumptions, and analytic findings were validated through peer review with external experts where possible. Limitations include the evolving nature of approvals and payer policy decisions; therefore, the analysis emphasizes structural trends and strategic implications rather than transient market estimations, and readers are advised to consider local regulatory announcements and procurement cycles when applying insights.

A concise conclusion synthesizing clinical advances, system readiness, and policy levers that together determine the equitable impact of prevention strategies

The collective evidence points to a rapidly evolving prevention landscape where product innovation, delivery models, and policy choices jointly determine the trajectory of access and equity. Long-acting formulations and diversified product portfolios expand clinical options, but their impact will depend on health system readiness, payer alignment, and targeted outreach to populations with the highest unmet need. Cost dynamics, influenced by generic competition and trade policy, will shape procurement decisions and the sustainability of public programs, reinforcing the need for proactive supply chain management and strategic payer engagement.

Looking ahead, successful stakeholders will be those that translate clinical efficacy into practical delivery by integrating service delivery redesign, digital tools, and community partnerships. By focusing on equitable access, resilience against policy shocks, and evidence-driven engagement with payers and providers, organizations can maximize the public health benefits of prevention innovations while maintaining commercial viability and ethical stewardship of resources.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pre-Exposure Prophylaxis Market, by Product Type

  • 8.1. Branded
    • 8.1.1. Descovy
    • 8.1.2. Truvada
  • 8.2. Generic

9. Pre-Exposure Prophylaxis Market, by Form

  • 9.1. Injectable
  • 9.2. Oral

10. Pre-Exposure Prophylaxis Market, by Distribution Channel

  • 10.1. Online Pharmacies
  • 10.2. Offline Pharmacies

11. Pre-Exposure Prophylaxis Market, by End User

  • 11.1. Clinics
  • 11.2. Home Care
  • 11.3. Hospitals

12. Pre-Exposure Prophylaxis Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Pre-Exposure Prophylaxis Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Pre-Exposure Prophylaxis Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Pre-Exposure Prophylaxis Market

16. China Pre-Exposure Prophylaxis Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Accord Healthcare Inc.
  • 17.6. Amneal Pharmaceuticals, Inc.
  • 17.7. Aurobindo Pharma Ltd.
  • 17.8. Cipla Ltd.
  • 17.9. Dr. Reddy's Laboratories Ltd.
  • 17.10. Fresenius Kabi AG
  • 17.11. Gilead Sciences, Inc.
  • 17.12. Hetero Labs Limited
  • 17.13. Lupin Limited
  • 17.14. Merck & Co., Inc.
  • 17.15. Mylan N.V.
  • 17.16. Sun Pharmaceutical Industries Ltd.
  • 17.17. Teva Pharmaceutical Industries Ltd.
  • 17.18. Viatris Inc.
  • 17.19. ViiV Healthcare Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DESCOVY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DESCOVY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DESCOVY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY TRUVADA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY TRUVADA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY TRUVADA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY OFFLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY OFFLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 42. AMERICAS PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 47. NORTH AMERICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. LATIN AMERICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 58. LATIN AMERICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. MIDDLE EAST PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. MIDDLE EAST PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. MIDDLE EAST PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. AFRICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. AFRICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. ASEAN PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. ASEAN PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. ASEAN PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. GCC PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GCC PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. GCC PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 99. GCC PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 100. GCC PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. GCC PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPEAN UNION PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPEAN UNION PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPEAN UNION PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. BRICS PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. BRICS PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. BRICS PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. BRICS PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. G7 PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. G7 PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. G7 PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 117. G7 PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 118. G7 PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. G7 PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. NATO PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. NATO PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. NATO PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 123. NATO PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 124. NATO PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. NATO PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. UNITED STATES PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. UNITED STATES PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. UNITED STATES PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. UNITED STATES PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. CHINA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. CHINA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. CHINA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 136. CHINA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 137. CHINA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. CHINA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)